Why semaglutide can make you feel sick — and what the data actually shows

What the STEP 1 trial data actually recorded, and what it means in practice

The STEP 1 results gave us the clearest picture yet of how often nausea appears with semaglutide 2.4mg. Just over four in ten participants reported it at some point across the 68 weeks, but that number is cumulative, it captures everyone who felt sick even briefly at any dose level during the whole study. The more useful figure for most readers is that severe nausea was far less common, and that the highest rates clustered around the early titration phase, when doses are being stepped up from 0.25mg toward maintenance.

The NHS patient information for semaglutide classifies nausea as a very common side effect (affecting more than one in ten users), alongside vomiting, diarrhoea, constipation, stomach pain, and burping. This is consistent with how GLP-1 medicines work: semaglutide slows the rate at which the stomach empties, which suppresses appetite but also means food sits longer than the gut is used to. That unfamiliar delay is largely what produces the queasy sensation, particularly in the first few days after starting or moving to a higher dose.

One practical habit that many people find useful: before each injection, spend thirty seconds thinking through what you ate in the last hour and how fast. Eating more slowly, and stopping well before feeling full, consistently comes up as the single adjustment that makes the biggest difference in the weeks after a dose increase. It takes no equipment and costs nothing to try.

Why the timing matters, and when nausea is most likely to strike

Nausea on semaglutide tends to follow a recognisable pattern. It is most pronounced in the first two to seven days after a new dose, then fades as your digestive system recalibrates. For most people on the standard titration schedule (roughly four weeks at each dose level) this means a brief rough patch at the start of each rung, followed by a more comfortable stretch before the next increase.

This pattern is one reason the titration schedule exists at all. Starting at 0.25mg and moving slowly upward is not about therapeutic effect at the lower doses; it is designed to let your gut adapt gradually so that by the time you reach 1.7mg or 2.4mg, the adjustment is far less jarring than it would have been jumping straight in. If nausea is making the current dose genuinely difficult to tolerate, that is a conversation worth having with your prescriber before automatically moving up, slowing the titration is a recognised clinical option, not a sign that treatment is failing.

You can read more about the full range of effects people notice across the Wegovy treatment journey on our Wegovy side effects overview, which covers everything from the GI symptoms to less commonly discussed reactions. For a deeper look at the mechanism behind the sickness specifically, our page on why semaglutide makes you feel sick goes into the gastric-emptying science in more detail.

When nausea signals something that needs urgent attention

Most nausea on semaglutide is unpleasant but not dangerous. There are two situations where it should not be left to pass on its own.

First, if vomiting or diarrhoea is severe enough that you cannot keep fluids down for more than a day, dehydration becomes a real risk, and dehydration can in turn affect kidney function. Contact your GP or NHS 111 if you are struggling to stay hydrated.

Second, and more urgently: stomach pain that is severe, persistent, and radiates toward the back (with or without vomiting) can be a sign of acute pancreatitis. In January 2026 the MHRA issued a Drug Safety Update specifically highlighting pancreatitis as a known but infrequent serious risk with GLP-1 medicines; the guidance is clear that this symptom pattern warrants urgent medical assessment, not a wait-and-see approach. You can report any suspected side effect through the MHRA Yellow Card scheme, which helps regulators build a fuller picture of how these medicines behave in real-world use. It is also worth being aware that our page on the Wegovy blindness risk covers another infrequent but serious safety signal that has received attention in recent clinical literature.

If you are generally tolerating treatment but finding the nausea disruptive, our page on managing nausea on semaglutide sets out the practical strategies prescribers most often recommend, from meal composition to hydration timing. For questions about whether the cost of treatment makes sense for your situation, our Wegovy cost page sets out what private treatment typically involves.

Getting support, and what a clinical review can offer

If nausea is making you wonder whether semaglutide is right for you, a prescriber is the right person to ask. They can look at when your symptoms are occurring, which dose you are on, how long it has been going on, and whether slowing the titration, adjusting timing, or reviewing your eating habits alongside the medicine would help. This is not a box-ticking exercise, it is the kind of clinical judgement that turns raw trial data into a plan that actually works for you as an individual.

At nume, every repeat order is reviewed by a GPhC-registered prescriber before it is dispensed. That review exists precisely so that questions like this one (is this nausea normal, should I slow my dose increase, am I safe to continue) have somewhere to go. You can also find more about our clinical team on the prescriber profile page, and read a broader overview of Wegovy as a treatment if you are still weighing up your options.

If you are thinking about starting treatment or would like your current plan reviewed, check your eligibility with a free consultation. It takes a few minutes, costs nothing, and is read the same day by a real clinician.